Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

$20m-$39.9m

Jasper springs to life with $35m
Building on translational science from Stanford, Jasper has secured funding to progress its Amgen-licensed conditioning agent for patients awaiting stem cell transplants.
Heartseed to grow with series B funding
JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital have contributed to a $25.8m round for Keio University's heart failure treatment developer.
V2Food tucks into $23.8m series A
V2Food has secured series A funding on the back of its strategic partnership with burger retail chain Hungry Jack's.
Sera Prognostics diagnoses $36m series D
Based on research from Brigham Young University and University of Utah, Sera has added $36m to its funding vault to drive commercialisation of its blood testing system PreTRM.
EpicentRx rustles up $35m
Building on UCSD intellectual property, EpicentRx is working on immunotherapy drugs intended to target the body's non-specific and adaptive specific immune function synchronously.
WealthNavi coordinates $37.6m round
UTokyo Innovation Platform is among a long list of investors that have backed a $37.6m funding round for WealthNavi.
Acticor conjures up $24.7m series B
The Inserm spinout secured a $7.8m series B extension and boosted its portfolio with the acquisition of AVCare, a Satt Ouest Valorisation-allied business.
Yikon yields $31m series C
Guangzhou Kingmed has led a $31m series C round for genome sequencing company Yikon Genomics, which was spun out of Harvard University five years ago.

Other News

Shape boxes up $35.5m
UCSD-founded Shape Therapeutics has collected series A cash from NEA and CureDuchenne Ventures to progress its RNA gene editing technology.
PierianDx clinches $27m series B
Genomics bioinformatics platform developer PierianDx, a Washington University in St Louis spinout, has raised fresh capital to advance its business strategy.
Gojo goes to corporates for series C funding
Dai-ichi Life has led the final close for the Japan-based financial technology developer’s $38.8m series C round, which was already backed by Tokyo University of Science Investment Management Company.
MiroBio signals for $33.1m
University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from OSI and GlaxoSmithKline’s SR One.
Elicio aligns itself with Livzon for $33m
Livzon Pharmaceutical Group has been identified as an investor by MIT spinout Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.
ZielBio reaches $25.1m series A target
Partners HealthCare has co-led a series A round for ZielBio to drive forward the development of a cancer treatment based on research at University of Virginia.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg

Login